| Multiple Myeloma
Mozobil vs Sarclisa
Side-by-side clinical, coverage, and cost comparison for multiple myeloma.Deep comparison between: Mozobil vs Sarclisa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSarclisa has a higher rate of injection site reactions vs Mozobil based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sarclisa but not Mozobil, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mozobil
Sarclisa
At A Glance
SC injection
Once daily for up to 4 days
CXCR4 antagonist
IV infusion
Every 1-4 weeks
CD38-directed cytolytic antibody
Indications
- Lymphoma, Non-Hodgkin
- Multiple Myeloma
- Multiple Myeloma
Dosing
Lymphoma, Non-Hodgkin, Multiple Myeloma 0.24 mg/kg SC (or 20 mg fixed dose for patients <=83 kg) once daily approximately 11 hours prior to apheresis for up to 4 consecutive days, following filgrastim 10 mcg/kg once daily for 4 days; maximum 40 mg/day.
Renal Impairment (CrCl <=50 mL/min) Reduce dose by one-third to 0.16 mg/kg SC (or 13 mg fixed dose for patients <=83 kg); maximum 27 mg/day.
Multiple Myeloma (with pomalidomide and dexamethasone) 10 mg/kg IV weekly in cycle 1 (days 1, 8, 15, 22 of a 28-day cycle), then every 2 weeks (days 1, 15) from cycle 2 onward.
Multiple Myeloma (with carfilzomib and dexamethasone) 10 mg/kg IV weekly in cycle 1, then every 2 weeks from cycle 2 onward.
Multiple Myeloma (with bortezomib, lenalidomide, and dexamethasone) 10 mg/kg IV on days 1, 8, 15, 22, and 29 of cycle 1 (42-day cycle); every 2 weeks in cycles 2-17; every 4 weeks from cycle 18 onward.
Contraindications
- History of hypersensitivity to plerixafor
- Severe hypersensitivity to isatuximab-irfc or any of its excipients
Adverse Reactions
Most common (>=10%) Diarrhea, nausea, injection site reactions, fatigue, headache, arthralgia, dizziness, vomiting
Serious Anaphylactic shock, hypersensitivity reactions, tumor cell mobilization, hyperleukocytosis, decreased platelet counts, splenic enlargement
Postmarketing Splenomegaly, splenic rupture, anaphylactic reactions including anaphylactic shock, abnormal dreams and nightmares
Most common (>=20%) Upper respiratory tract infection, infusion-related reactions, pneumonia, diarrhea, fatigue, hypertension, dyspnea, insomnia, bronchitis, cough, back pain, peripheral sensory neuropathy, musculoskeletal pain, cataract, constipation, peripheral edema, rash
Serious Pneumonia, upper respiratory tract infections, febrile neutropenia, cardiac failure
Pharmacology
Plerixafor is a CXCR4 chemokine receptor inhibitor that blocks binding of stromal cell-derived factor-1alpha (SDF-1alpha), disrupting HSC anchoring in the bone marrow and mobilizing hematopoietic stem cells to the peripheral blood for apheresis collection.
Isatuximab-irfc is an IgG1-derived monoclonal antibody that binds to CD38 expressed on hematopoietic and tumor cells, inducing apoptosis and activating immune effector mechanisms including ADCC, ADCP, and CDC, while also inhibiting CD38 ADP-ribosyl cyclase activity and suppressing CD38-positive T-regulatory cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mozobil
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Sarclisa
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Mozobil
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Sarclisa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Mozobil
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Sarclisa
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Chemotherapy Induced Neutropenia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Multiple Myeloma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MozobilView full Mozobil profile
SarclisaView full Sarclisa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.